Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma.
Twenty-one subjects with known bronchial hyperreactivity were prospectively randomized in double-blind fashion to receive one of two angiotensin-converting enzyme inhibitors (ACE-I), enalapril or spirapril, for three weeks. Spirometry and methacholine provocation were performed prior to, during, and following ACE-I usage. Three of 21 subjects developed a nonproductive cough. However, only one subject wheezed slightly. Spirometry and bronchial reactivity (PD20) were unchanged throughout the study.
Kaufman
J
J
Medical College of Wisconsin, Milwaukee.
Schmitt
S
S
Barnard
J
J
Busse
W
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D003371:Cough / Q000139:chemically induced; D004311:Double-Blind Method; D004361:Drug Tolerance; D004656:Enalapril / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D016210:Methacholine Chloride; D008875:Middle Aged; D011446:Prospective Studies; D016037:Single-Blind Method
D000806:Angiotensin-Converting Enzyme Inhibitors; D016210:Methacholine Chloride; D004656:Enalapril; C052555:spirapril